PathAI
PathAI sells AISight Dx, an FDA-cleared image management system with AI applications, to clinical labs and health systems. It also sells AI models, clinical-trial endpoint tools and central lab services to biopharma. Its customers and partners include Labcorp, MedStar Health and University Hospital Zurich. It raised about $255M in venture funding through a 2021 Series C. In May 2026 Roche agreed to acquire it for $750M upfront plus up to $300M in milestones, with closing expected in the second half of 2026.
Funding
Every round, secondary, debt facility or acquisition involving PathAI that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in